Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PCS499 in Necrobiosis Lipoidica
NCT03698864Phase 2Completed
- Sponsor
- Processa Pharmaceuticals, Inc.
- Start
- Nov 2018
- Primary completion
- Feb 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of PCS-499 in necrobiosis lipoidica (NLD), sponsored by Processa Pharmaceuticals, Inc. Primary endpoint: Number of Participants With Adverse Events at 12 months. Started Nov 2018; status: completed.
02
Drugs
PCS-499
03
Conditions
necrobiosis lipoidica (NLD)
Beyond the preview
Go deeper on NCT03698864.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03698864.